E Premkumar Reddy
Overview
Explore the profile of E Premkumar Reddy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
2707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karunaraj P, Cao E, Singh H, Luf M, Baker S, Reddy E, et al.
bioRxiv
. 2025 Feb;
PMID: 39974993
Germline mutations that increase signaling through the Ras pathway can cause developmental disorders called RASopathies. The RASopathy Costello syndrome has been described to present with hallmarks that include short stature,...
2.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, et al.
Cancer Discov
. 2023 Sep;
13(12):2584-2609.
PMID: 37676710
Significance: Our study shows that specialized eIF3B-dependent translation of specific mRNAs released upon downregulation of the master transcription factor MITF confers castration resistance and immune evasion in lethal prostate cancer....
3.
Baker S, Poulikakos P, Irie H, Parekh S, Reddy E
Genes Cancer
. 2022 Sep;
13:21-45.
PMID: 36051751
The cell cycle is regulated in part by cyclins and their associated serine/threonine cyclin-dependent kinases, or CDKs. CDK4, in conjunction with the D-type cyclins, mediates progression through the G phase...
4.
Xia Y, Inoue K, Du Y, Baker S, Reddy E, Greenblatt M, et al.
Nat Commun
. 2022 Jul;
13(1):3920.
PMID: 35798734
It is well-established that receptor activator of NF-κB ligand (RANKL) is the inducer of physiological osteoclast differentiation. However, the specific drivers and mechanisms driving inflammatory osteoclast differentiation under pathological conditions...
5.
Chen X, Barrero C, Vasquez-Del Carpio R, Reddy E, Fecchio C, Merali S, et al.
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959389
Posiphen tartrate (Posiphen) is an orally available small molecule that targets a conserved regulatory element in the mRNAs of amyloid precursor protein (APP) and α-synuclein (αSYN) and inhibits their translation....
6.
Sato K, Padgaonkar A, Baker S, Cosenza S, Rechkoblit O, Subbaiah D, et al.
Nat Commun
. 2021 Aug;
12(1):4671.
PMID: 34344863
Triple negative breast cancer (TNBC) remains challenging because of heterogeneous responses to chemotherapy. Incomplete response is associated with a greater risk of metastatic progression. Therefore, treatments that target chemotherapy-resistant TNBC...
7.
Yan C, Saleh N, Yang J, Nebhan C, Vilgelm A, Reddy E, et al.
Mol Cancer
. 2021 Jun;
20(1):85.
PMID: 34092233
Background: While immune checkpoint blockade (ICB) is the current first-line treatment for metastatic melanoma, it is effective for ~ 52% of patients and has dangerous side effects. The objective here...
8.
Baker S, Cosenza S, Athuluri-Divakar S, Reddy M, Vasquez-Del Carpio R, Jain R, et al.
Mol Cell
. 2020 Jul;
79(1):180-190.e4.
PMID: 32619468
Rigosertib is a styryl benzyl sulfone that inhibits growth of tumor cells and acts as a RAS mimetic by binding to Ras binding domains of RAS effectors. A recent study...
9.
Baker S, Cosenza S, Reddy M, Reddy E
Oncotarget
. 2019 Apr;
10(20):1932-1942.
PMID: 30956775
Aberrant signaling triggered by oncogenic or hyperactive RAS proteins contributes to the malignant phenotypes in a significant percentage of myeloid malignancies. Of these, juvenile myelomonocytic leukemia (JMML), an aggressive childhood...
10.
Padgaonkar A, Rechkoblit O, Vasquez-Del Carpio R, Pallela V, Venkata Subbaiah D, Cosenza S, et al.
Oncotarget
. 2019 Feb;
9(102):37753-37765.
PMID: 30701029
Overexpression and constitutive activation of CYCLIN D1 and Casein Kinase 2 are common features of many hematologic malignancies, including mantle cell lymphoma (MCL) and leukemias such as T-cell acute lymphoblastic...